Literature DB >> 11483595

Oxazolidinones mechanism of action: inhibition of the first peptide bond formation.

U Patel1, Y P Yan, F W Hobbs, J Kaczmarczyk, A M Slee, D L Pompliano, M G Kurilla, E V Bobkova.   

Abstract

Oxazolidinones are potent inhibitors of bacterial protein biosynthesis. Previous studies have demonstrated that this new class of antimicrobial agent blocks translation by inhibiting initiation complex formation, while post-initiation translation by polysomes and poly(U)-dependent translation is not a target for these compounds. We found that oxazolidinones inhibit translation of natural mRNA templates but have no significant effect on poly(A)-dependent translation. Here we show that various oxazolidinones inhibit ribosomal peptidyltransferase activity in the simple reaction of 70 S ribosomes using initiator-tRNA or N-protected CCA-Phe as a P-site substrate and puromycin as an A-site substrate. Steady-state kinetic analysis shows that oxazolidinones display a competitive inhibition pattern with respect to both the P-site and A-site substrates. This is consistent with a rapid equilibrium, ordered mechanism of the peptidyltransferase reaction, wherein binding of the A-site substrate can occur only after complex formation between peptidyltransferase and the P-site substrate. We propose that oxazolidinones inhibit bacterial protein biosynthesis by interfering with the binding of initiator fMet-tRNA(i)(Met) to the ribosomal peptidyltransferase P-site, which is vacant only prior to the formation of the first peptide bond.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483595     DOI: 10.1074/jbc.M102966200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  How antibiotics kill bacteria: from targets to networks.

Authors:  Michael A Kohanski; Daniel J Dwyer; James J Collins
Journal:  Nat Rev Microbiol       Date:  2010-05-04       Impact factor: 60.633

3.  The Oxazolidinones.

Authors:  Gerald A. Evans
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

4.  R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.

Authors:  Eugene Skripkin; Timothy S McConnell; Joseph DeVito; Laura Lawrence; Joseph A Ippolito; Erin M Duffy; Joyce Sutcliffe; François Franceschi
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

5.  Characterization of a novel antibacterial agent that inhibits bacterial translation.

Authors:  Nina Böddeker; Gina Bahador; Craig Gibbs; Eric Mabery; John Wolf; Lianhong Xu; Julia Watson
Journal:  RNA       Date:  2002-09       Impact factor: 4.942

6.  In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.

Authors:  Ming Zhang; Claudia Sala; Neeraj Dhar; Anthony Vocat; Vasan K Sambandamurthy; Sreevalli Sharma; Gwendolyn Marriner; V Balasubramanian; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

Review 7.  Context-Specific Action of Ribosomal Antibiotics.

Authors:  Nora Vázquez-Laslop; Alexander S Mankin
Journal:  Annu Rev Microbiol       Date:  2018-06-15       Impact factor: 15.500

8.  In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria.

Authors:  Sang-Hun Oh; Josep Kim; Sung-Yoon Baek; Sang-Eun Chae; Hee-Soo Park; Young-Lag Cho; Jin-Hwan Kwak
Journal:  Molecules       Date:  2017-03-03       Impact factor: 4.411

9.  Four new antibacterial xanthones from the marine-derived actinomycetes Streptomyces caelestis.

Authors:  Ling-Li Liu; Ying Xu; Zhuang Han; Yong-Xin Li; Liang Lu; Pok-Yui Lai; Jia-Liang Zhong; Xian-Rong Guo; Xi-Xiang Zhang; Pei-Yuan Qian
Journal:  Mar Drugs       Date:  2012-11-20       Impact factor: 5.118

Review 10.  Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds.

Authors:  Alfonsus Alvin; Kristin I Miller; Brett A Neilan
Journal:  Microbiol Res       Date:  2014-01-15       Impact factor: 5.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.